- Home
- MNR vs GLPG Comparison
MNR vs GLPG Comparison
Compare MNR & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNR
- GLPG
- Stock Information
- Founded
- MNR 2017
- GLPG 1999
- Country
- MNR United States
- GLPG Belgium
- Employees
- MNR N/A
- GLPG N/A
- Industry
- MNR
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- MNR
- GLPG Health Care
- Exchange
- MNR Nasdaq
- GLPG Nasdaq
- Market Cap
- MNR 1.7B
- GLPG 1.8B
- IPO Year
- MNR 2023
- GLPG 2005
- Fundamental
- Price
- MNR $15.33
- GLPG $27.42
- Analyst Decision
- MNR Strong Buy
- GLPG Sell
- Analyst Count
- MNR 3
- GLPG 4
- Target Price
- MNR $24.00
- GLPG $25.33
- AVG Volume (30 Days)
- MNR 418.2K
- GLPG 263.3K
- Earning Date
- MNR 08-12-2025
- GLPG 07-23-2025
- Dividend Yield
- MNR 18.18%
- GLPG N/A
- EPS Growth
- MNR 705.75
- GLPG N/A
- EPS
- MNR 1.56
- GLPG N/A
- Revenue
- MNR $941,846,000.00
- GLPG $311,493,731.00
- Revenue This Year
- MNR $4.44
- GLPG $0.78
- Revenue Next Year
- MNR $2.27
- GLPG N/A
- P/E Ratio
- MNR $9.81
- GLPG N/A
- Revenue Growth
- MNR 22.14
- GLPG 18.32
- 52 Week Low
- MNR $12.40
- GLPG $22.36
- 52 Week High
- MNR $20.94
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- MNR 72.83
- GLPG 44.30
- Support Level
- MNR $12.91
- GLPG $27.67
- Resistance Level
- MNR $15.08
- GLPG $29.28
- Average True Range (ATR)
- MNR 0.40
- GLPG 0.57
- MACD
- MNR 0.23
- GLPG -0.19
- Stochastic Oscillator
- MNR 94.15
- GLPG 13.10
About MNR Mach Natural Resources LP
Mach Natural Resources LP is an independent upstream oil and gas company. The company is focused on the acquisition, development and production of oil, natural gas, and NGL reserves in the Anadarko Basin region of Western Oklahoma, Southern Kansas, and the panhandle of Texas.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.